Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,112.20 -206.04 -1.35%
S&P 500 1,628.93 -22.88 -1.39%
Nasdaq 3,443.20 -38.98 -1.12%
Ticker Volume Price Price Delta
STOXX 50 2,683.98 -16.95 -0.63%
FTSE 100 6,348.82 -25.39 -0.40%
DAX 8,197.08 -32.43 -0.39%
Ticker Volume Price Price Delta
Nikkei 13,116.00 -129.18 -0.98%
Hang Seng 20,458.20 -528.72 -2.52%
S&P/ASX 200 4,743.20 -118.18 -2.43%
  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Zalicus Inc

+ Add to Watchlist

ZLCS:US

0.5601 USD 0.0051 0.92%

As of 20:10:00 ET on 06/19/2013.

Company Profile for Zalicus Inc (ZLCS)

Zalicus Inc is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The Company's drug pipeline includes an arthritis formula in phase 2 development.

Contact Information

Zalicus Inc

245 First Street
Cambridge, MA 02142
United States
Phone: 1-617-301-7000
Fax: 1-617-301-7010

Key Executives for Zalicus Inc (ZLCS)

Mark H N CorriganPresident/CEOJustin A RenzExec VP/CFO/Treasurer
Jason F ColeExec VP:Corporate Dev/Gen Cnsl

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil